CRC1607 | News - We are hiring

We are hiring

Become part of our dynamic team in the new DFG Collaborative Research Center 1607 “Towards immunomodulatory and anti(lymph)angiogenic therapies against age-related blinding eye diseases” starting April 2024! We are currently looking for dedicated postdocs and PhD students to join various research groups within our consortium.

As part of this ground-breaking initiative, you will have the opportunity to contribute to cutting-edge research aimed at understanding and targeting lymph/blood vessels and immune cells in age-related eye diseases. This unique SFB 1607 is the only (inter)national center of its kind and offers a unique opportunity to improve the lives of patients with blinding eye diseases.

Ideal candidates will have motivation, curiosity and creativity as well as strong problem solving and excellent communication skills. PhD applicants should have a Master’s degree in biology, biomedical sciences, neuroscience or a related field, while postdoctoral applicants should have a PhD in biology, biochemistry, biophysics, medicine or related life sciences.

In addition to a stimulating working environment, we offer a secure job with a company pension scheme and regular working hours. Whether full or part-time, with or without children, we offer numerous support services to make you feel at home with us. You will be welcomed into an interdisciplinary team that values mutual respect and collaboration, with extensive training opportunities through our integrated graduate school “Eye and Inflammation” (EI).

Join us in shaping the future of eye disease research while building your own professional network in this exciting CRC!

Information on our individual subprojects and their project leaders can be found on this homepage. Currently we can still offer postdoctoral positions in the projects B01, C04 and Z01. PhD’s are sought in the subprojects A01, A02, A03, A04, A05, B04, C01, C02, C06 and Z02

Apply now by e-mail to If you have any questions, please do not hesitate to contact us.